NEW YORK, May 23, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Neurotrope, Inc. (NASDAQ:NTRP) who purchased shares between January 7, 2016, and April 28, 2017. The action, which was filed in the U.S. District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
The complaint alleges that throughout the Class Period Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
Shareholders have until July 17, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/neurotrope-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook
Google Halts UK YouTube TV Measurement Service After Legal Action
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India
The Maire - EuroChem Case: Three Lessons for Global Business
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 



